Double-blind, placebo-controlled, pilot trial of botulinum toxin A in restless legs syndrome.
Nahab
Fatta B
FB
Human Motor Control Section, NINDS/NIH, 10 Center Drive, Bldg 10, Room 5N226, Bethesda, MD 20892-1428, USA. nahabf@ninds.nih.gov
Peckham
Elizabeth L
EL
Hallett
Mark
M
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007267:Injections; D007866:Leg; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000139:chemically induced; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D012148:Restless Legs Syndrome / Q000188:drug therapy*; D017211:Treatment Failure
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
Neurology. 2006 Sep 26;67(6):1034-9
16931507
Med Hypotheses. 2007;69(3):497-501
17363179
J Clin Sleep Med. 2006 Jul 15;2(3):275-8
17561538
Sleep Med. 2003 Mar;4(2):121-32
14592342
Clin Neurophysiol. 2004 Sep;115(9):1975-88
15294200
Mov Disord. 1995 Sep;10(5):634-42
8552117